Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100VZL4
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 122
MetricValuePeriodScopeSource row
Revenue¥64.1bn2024-04-01 → 2025-03-31Cons.Net sales
Revenue¥62.8bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31dCons.Net sales (5-year summary)
Revenue¥56.6bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Operating income¥5.3bn2024-04-01 → 2025-03-31Cons.Operating income
Operating income¥6.5bn2023-04-01 → 2024-03-31Cons.Operating income
Ordinary income¥5.1bn2024-04-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥6.5bn2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥4.9bn2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥6.2bn2024-04-01 → 2025-03-31Cons.Income before income taxes
Profit before tax¥9.9bn2023-04-01 → 2024-03-31Cons.Income before income taxes
Net income (owners)¥5.1bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥5.1bn2024-04-01 → 2025-03-31Cons.Profit loss
Net income¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss
Total assets¥100.5bnat 2025-03-31Cons.Assets
Total assets¥90.7bnat 2024-03-31Cons.Assets
Total assets¥87.1bnat 2023-03-31dCons.Total assets (5-year summary)
Total assets¥83.3bnat 2022-03-31dCons.Total assets (5-year summary)
Total liabilities¥31.3bnat 2025-03-31Cons.Liabilities
Total liabilities¥28.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥69.2bnat 2025-03-31Cons.Net assets
Net assets / equity¥61.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31dCons.Net assets
Net assets / equity¥48.9bnat 2022-03-31dCons.Net assets (5-year summary)
Cash and deposits¥10.6bnat 2025-03-31Cons.Cash and deposits
Cash and deposits¥13.7bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥10.6bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥16.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.5bnat 2023-03-31dCons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥2.5bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥1.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥6.1bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥1.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥179.952024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥266.512023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥2,302.61at 2025-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥2,186.1at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,928.14at 2023-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31dCons.Net assets per share (5-year summary)
Equity ratio65.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
ROE8.0%2024-04-01 → 2025-03-31Cons.Rate of return on equity (5-year summary)
ROE13.0%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE8.2%2022-04-01 → 2023-03-31dCons.Rate of return on equity (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
Employees1,632at 2025-03-31Cons.Number of employees
Employees762at 2024-03-31Cons.Number of employees
Employees747at 2023-03-31dCons.Number of employees
Employees777at 2022-03-31dCons.Number of employees
Revenue¥4.5bn2024-04-01 → 2025-03-31StandaloneOperating revenue1
Revenue¥3.7bn2023-04-01 → 2024-03-31StandaloneOperating revenue1
Revenue¥1.7bn2022-04-01 → 2023-03-31dStandaloneOperating revenue1 (5-year summary)
Revenue¥1.4bn2021-04-01 → 2022-03-31dStandaloneOperating revenue1 (5-year summary)
Operating income¥3.2bn2024-04-01 → 2025-03-31StandaloneOperating income
Operating income¥2.5bn2023-04-01 → 2024-03-31StandaloneOperating income
Ordinary income¥3.2bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥2.5bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥603m2022-04-01 → 2023-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥717m2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥3.2bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Profit before tax¥2.5bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Net income¥3.2bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥2.5bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥591m2022-04-01 → 2023-03-31dStandaloneNet income loss (5-year summary)
Net income¥682m2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Total assets¥48.3bnat 2025-03-31StandaloneAssets
Total assets¥43.2bnat 2024-03-31StandaloneAssets
Total assets¥41.6bnat 2023-03-31dStandaloneTotal assets (5-year summary)
Total assets¥41.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥3.6bnat 2025-03-31StandaloneLiabilities
Total liabilities¥565mat 2024-03-31StandaloneLiabilities
Net assets / equity¥44.6bnat 2025-03-31StandaloneNet assets
Net assets / equity¥42.7bnat 2024-03-31StandaloneNet assets
Net assets / equity¥40.9bnat 2023-03-31dStandaloneNet assets
Net assets / equity¥40.7bnat 2022-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥5.4bnat 2025-03-31StandaloneCash and deposits
Cash and deposits¥2.2bnat 2024-03-31StandaloneCash and deposits
EPS (basic)¥111.572024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥87.12023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥20.952022-04-01 → 2023-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥23.792021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥552024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥402023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥162022-04-01 → 2023-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,574.11at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,506.47at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,447.55at 2023-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio92.5%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.7%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2023-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE7.2%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE5.9%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE1.5%2022-04-01 → 2023-03-31dStandaloneRate of return on equity (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued28,763,199at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2023-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees80at 2025-03-31StandaloneNumber of employees
Employees75at 2024-03-31StandaloneNumber of employees
Employees79at 2023-03-31dStandaloneNumber of employees
Employees74at 2022-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 57
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2025-03-3116 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2025-03-31¥325m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2025-03-31¥237m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2025-03-31¥88m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2025-03-31¥51m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2025-03-31¥2m
Reconciling Itemsreconcilingdepreciation2024-04-01 → 2025-03-31¥192m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2025-03-31−¥88m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2025-03-31−¥88m
Reconciling Itemsreconcilingsegment assetsat 2025-03-31¥31.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥1.3bn
Animal Health Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥3m
Animal Health Businessreportable segmentemployeesat 2025-03-3132 pure
Animal Health Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥7.2bn
Animal Health Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥7.2bn
Animal Health Businessreportable segmentsegment assetsat 2025-03-31¥4.2bn
Animal Health Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥300m
Oversea Businessreportable segmentemployeesat 2025-03-31857 pure
Oversea Businessreportable segmentsegment assetsat 2025-03-31¥14.9bn
Pharmaceutical Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥1.7bn
Pharmaceutical Businessreportable segmentemployeesat 2025-03-31635 pure
Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥56.7bn
Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥56.7bn
Pharmaceutical Businessreportable segmentsegment assetsat 2025-03-31¥49.6bn
Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥6.3bn
Total Of Reportable Segments And Otherssegment totaldepreciation2024-04-01 → 2025-03-31¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2025-03-31¥64.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2025-03-31¥64.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2025-03-31¥88m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2025-03-31¥68.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2025-03-31¥6.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2024-03-31¥226m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2024-03-31¥162m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2024-03-31¥64m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-03-31¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2024-03-31−¥125m
Reconciling Itemsreconcilingdepreciation2023-04-01 → 2024-03-31¥201m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingsegment assetsat 2024-03-31¥42.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥1.2bn
Animal Health Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥4m
Animal Health Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2024-03-31¥3.5bn
Animal Health Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥195m
Pharmaceutical Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥2.2bn
Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentsegment assetsat 2024-03-31¥45.0bn
Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥7.6bn
Total Of Reportable Segments And Otherssegment totaldepreciation2023-04-01 → 2024-03-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2024-03-31¥62.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2024-03-31¥62.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2024-03-31¥64m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2024-03-31¥48.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2024-03-31¥7.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,602
ItemContextValueUnit
Disposal of treasury stockCurrentYearDuration_ShareholdersEquityMember84000000JPY
Retirement of treasury stockCurrentYearDuration_CapitalSurplusMember-2535000000JPY
Retirement of treasury stockCurrentYearDuration_TreasuryStockMember2535000000JPY
Retirement of treasury stockCurrentYearDuration_ShareholdersEquityMember－JPY
Transfer to capital surplus from retained earningsCurrentYearDuration_CapitalSurplusMember651000000JPY
Transfer to capital surplus from retained earningsCurrentYearDuration_RetainedEarningsMember-651000000JPY
Transfer to capital surplus from retained earningsCurrentYearDuration_ShareholdersEquityMember－JPY
Total changes of items during the periodCurrentYearDuration_CapitalStockMember－JPY
Total changes of items during the periodCurrentYearDuration_CapitalSurplusMember-1848000000JPY
Total changes of items during the periodCurrentYearDuration_RetainedEarningsMember3173000000JPY
Total changes of items during the periodCurrentYearDuration_TreasuryStockMember2583000000JPY
Total changes of items during the periodCurrentYearDuration_ShareholdersEquityMember3908000000JPY
Net assetsCurrentYearInstant_CapitalStockMember1197000000JPY
Net assetsCurrentYearInstant_CapitalSurplusMember－JPY
Net assetsCurrentYearInstant_RetainedEarningsMember59545000000JPY
Net assetsCurrentYearInstant_TreasuryStockMember-704000000JPY
Net assetsCurrentYearInstant_ShareholdersEquityMember60039000000JPY
Net assetsPrior1YearInstant_ValuationDifferenceOnAvailableForSaleSecuritiesMember4790000000JPY
Net assetsPrior1YearInstant_ForeignCurrencyTranslationAdjustmentMember424000000JPY
Net assetsPrior1YearInstant_RemeasurementsOfDefinedBenefitPlansMember584000000JPY
Net assetsPrior1YearInstant_ValuationAndTranslationAdjustmentsMember5799000000JPY
Net assetsPrior1YearInstant_NonControllingInterestsMember－JPY
Net assetsPrior1YearInstant61930000000JPY
Dividends from surplusCurrentYearDuration-1275000000JPY
Profit loss attributable to owners of parentCurrentYearDuration5101000000JPY
Purchase of treasury stockCurrentYearDuration-0JPY
Disposal of treasury stockCurrentYearDuration84000000JPY
Retirement of treasury stockCurrentYearDuration－JPY
Transfer to capital surplus from retained earningsCurrentYearDuration－JPY
Net changes of items other than shareholders equityCurrentYearDuration_ValuationDifferenceOnAvailableForSaleSecuritiesMember62000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ForeignCurrencyTranslationAdjustmentMember-424000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_RemeasurementsOfDefinedBenefitPlansMember-167000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ValuationAndTranslationAdjustmentsMember-528000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonControllingInterestsMember3885000000JPY
Net changes of items other than shareholders equityCurrentYearDuration3356000000JPY
Total changes of items during the periodCurrentYearDuration_ValuationDifferenceOnAvailableForSaleSecuritiesMember62000000JPY
Total changes of items during the periodCurrentYearDuration_ForeignCurrencyTranslationAdjustmentMember-424000000JPY
Total changes of items during the periodCurrentYearDuration_RemeasurementsOfDefinedBenefitPlansMember-167000000JPY
Total changes of items during the periodCurrentYearDuration_ValuationAndTranslationAdjustmentsMember-528000000JPY
Total changes of items during the periodCurrentYearDuration_NonControllingInterestsMember3885000000JPY
Total changes of items during the periodCurrentYearDuration7265000000JPY
Net assetsCurrentYearInstant_ValuationDifferenceOnAvailableForSaleSecuritiesMember4853000000JPY
Net assetsCurrentYearInstant_ForeignCurrencyTranslationAdjustmentMember－JPY
Net assetsCurrentYearInstant_RemeasurementsOfDefinedBenefitPlansMember417000000JPY
Net assetsCurrentYearInstant_ValuationAndTranslationAdjustmentsMember5271000000JPY
Net assetsCurrentYearInstant_NonControllingInterestsMember3885000000JPY
Net assetsCurrentYearInstant69195000000JPY
Income before income taxesPrior1YearDuration9862000000JPY
Income before income taxesCurrentYearDuration6192000000JPY
Depreciation and amortization ope cfPrior1YearDuration2662000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2025-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass